Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
05 December 2019 | Story Nonsindiso Qwabe
Laptop read more
At the handover were, from the left: Dikgapane Makhetha, Officer in the Department of Community Engagement; Zwelinjani Mbatha; Ntsiwoa Andries (both teachers at Botlehadi); and Legopheng Maphile, Assistant Director: Library Marketing and Community Engagement at UFS LIS.

School libraries are an important resource for young minds. International research has shown that school libraries are beneficial to the academic development and progress of learners. A fully stocked and functional library within a school can improve learner performance and reading abilities by up to 8%. 

A seemingly simple gift of a laptop will therefore go a long way in ensuring that Botlehadi Primary School in Turflaagte has a functional library that will be a reading haven for all its learners.

Inspiring change

The laptop was a donation to the school by the University of the Free State Library and Information Services (UFS LIS) and the Department of Community Engagement. Before the handover on 26 November, it was pre-loaded with software that would allow the school to create an inventory of all books in its library, track their books, and consolidate their learning resources in one central place, like any fully-fledged library. 

Botlehadi was one of the schools that benefited from the Mandela Day project in July, when the two divisions gave the school’s library a much-needed revamp. A laptop was promised, and the school’s representatives were all smiles when they finally held it in their hands. 

Botlehadi teacher, Ntsiwoa Andries, said the school was beyond grateful for the laptop and the stability it would bring to their library. With their learner count numbering 1 800, Andries said keeping track of their books had become quite a daunting task. 

“The books are there, but we have a lacking library system. We don’t even have a librarian to manage the library for us. This laptop will help us to store our books and know which books we have, and which ones have been taken out by learners. It was easy to lose books because we had no effective system.”

Promoting a culture of reading

Andries said the school is a leader in its community by encouraging a culture of reading for both learners and their parents.

“We have books for all ages and even invite the parents to make use of the library facilities. It feels good to know that we will be able to give our community better access to books, because most of them cannot afford to buy books. They will finally know how it feels to have a wide variety of books to choose from.”

As a librarian, Postgraduate Research Librarian, Carmel Nel, said she knows the difference a small school-library system can make for a school like Botlehadi.

“When we first visited the school in July, we felt their strong need for a laptop in order to track their books. After approaching the Bloemfontein Rotary Club for help, we were finally able to fulfil our promise to the school. The laptop’s management software will allow them to effectively plan and distribute their resources and manage book circulation.”

Legopheng Maphile, Assistant Director: Library Marketing and Community Engagement at UFS LIS, said: “We are just planting a seed now, but there’s a lot of watering that needs to be done. We promised to donate this laptop before we even had it, and today we’re excited to be making an impact.”

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept